Vitti Labs

What Vitti Labs does

Vitti Labs is a privately held LLC headquartered in Liberty, Missouri, founded in 2019 to manufacture human cellular and tissue-based products (HCT/Ps) for clinical use. The company operates as an AATB-accredited, cGMP-certified, and FDA-registered (21 CFR Part 1271) tissue bank that produces 361 HCT/Ps under minimal-manipulation processing guidelines from bio-ethically sourced US birth tissue. Its commercial portfolio centers on birth-tissue-derived materials, mesenchymal stem cell (MSC) products, and extracellular vesicle preparations for homologous use by medical professionals across clinical settings.

The company runs an R&D pipeline that targets an unusually broad set of indications: VL-OV11 is in Phase II for infertility (POI/PCOS); VL-PX10 and VL-P22 are in expanded access for Covid and pulmonary fibrosis / Long-Haul Covid / COPD; UCT-MSC plus biomaterials and UC-Blood Biomolecules are in pre-clinical development for Crohn's Disease, Duchenne Muscular Dystrophy, and Autism; and a MSC Exosomal Eye Serum is in pre-clinical for age-related macular degeneration and glaucoma. Quality control rests on third-party lot testing covering sterility (USP 71), endotoxin, environmental controls (USP 1116), and broad pathogen screening, with execution anchored by university research partnerships and IRB studies.

Vitti Labs distributes exclusively through a direct enterprise field-sales motion to medical professionals in the United States; pricing is quote-based and not publicly disclosed, and the website is restricted to medical-professional viewers. The company is owner-operated with no disclosed institutional funding, parent entity, or public ownership, and no revenue, headcount, or transaction data is available in the source material. Revenue mechanics are anchored on one-time HCT/P product sales, with the pipeline positioned as a future driver of clinical-trial and expanded-access revenue rather than near-term commercial scale.

Name

Vitti Labs

Legal name

Vitti Labs, LLC

Website

https://vittilabs.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Vitti Labs is an AATB-accredited, cGMP-certified, FDA-registered tissue bank in Liberty, Missouri that manufactures bio-ethically sourced 361 HCT/P products (birth tissue, MSCs, extracellular vesicles) for medical professionals and runs a clinical-stage regenerative medicine pipeline across multiple indications.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAGAGAF

Analytical Development & QC Testing (Release/Stability/Potency)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

SECONDARYHLAGAEAI

Sample Logistics, Biorepository & IVD Kit Management (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAJADAF

Clinical Trials Authorization & Oversight (GCP)

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

Keywords

• Regenerative medicine manufacturing
• Human tissue products
• Cellular therapy products
• Tissue banking services
• Birth tissue products

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. HCT/P Product Sales: Revenue from manufacturing and selling human cellular and tissue-based products (HCT/Ps) for homologous use in clinical settings. Products include birth tissue-derived materials for medical professionals supporting patient quality of life.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Vitti Labs manufactures and supplies bio-ethically sourced human cellular and tissue-based products (HCT/Ps) regulated as 361 HCT/Ps for homologous use in clinical settings. The portfolio serves medical professionals in clinical practice and supports an investigational pipeline of therapeutic candidates (infertility, Covid/pulmonary, Crohn's, DMD, autism, ophthalmology) processed under AATB, cGMP, and FDA-registered standards.

Product overview

Vitti Labs is an AATB accredited, cGMP certified, and FDA registered tissue bank offering a portfolio of bio-ethically manufactured human birth tissue products (HCT/Ps) regulated as 361 HCT/Ps for homologous use in clinical settings. The company provides a comprehensive portfolio including core HCT/P products along with multiple therapeutic candidates in its pipeline: VL-OV11 for infertility, VL-PX10 & VL-P22 for Covid and pulmonary conditions, UCT-MSC + Biomaterials and UC-Blood Biomolecules for neurological/autoimmune conditions, and MSC Exosomal Eye Serum for ophthalmology applications. Manufacturing follows minimal manipulation guidelines with third-party lab testing for sterility, endotoxin, and environmental controls.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Cellular and Tissue-Based Products (HCT/Ps) Industry-leading portfolio of human cellular and tissue-based products regulated as 361 HCT/Ps under 21 CFR 1271.3(f)(1) for homologous use in clinical settings, manufactured via minimal-manipulation processing and bio-ethically sourced from U.S. donors. Sold to medical professionals and healthcare providers through a direct sales channel.
• VL-OV11 Named Vitti Labs therapeutic candidate for Infertility (POI/PCOS), currently in Clinical Trials Phase II under investigational status.
• VL-PX10 and VL-P22 Named Vitti Labs therapeutic candidates for Covid, pulmonary fibrosis in Long-Haul Covid patients, and COPD; reported as in expanded access for pulmonary fibrosis per source.
• UCT-MSC + Biomaterials Investigational Umbilical Cord Tissue Mesenchymal Stem Cells product combined with biomaterials, targeted at Crohn's Disease, Duchenne Muscular Dystrophy, and Autism; in pre-clinical safety and efficacy studies per source.
• UC-Blood Biomolecules Investigational Umbilical Cord Blood Biomolecules product targeted at Autism treatment; in pre-clinical safety and efficacy studies per source.
• MSC Exosomal Eye Serum Investigational Mesenchymal Stem Cell Exosomal Eye Serum targeted at Age-Related Macular Degeneration and Glaucoma; in pre-clinical development per source.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University Research PartnerscoreStrategic or Co-development PartnerVitti Labs conducts clinical research through university partnerships for therapeutic development including IND Applications and IRB Studies. Research focuses on human birth tissue bioavailable materials, mesenchymal stem cells, and extracellular vesicles for treating pulmonary disease, fertility, ophthalmology, and neurodegenerative diseases.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• Cryoport Systems: Public provider of temperature-controlled supply chain solutions for the life sciences industry, including cell and tissue logistics. Comparable as a biorepository-adjacent infrastructure provider supporting cell and tissue therapy supply chains.

Broad incumbents

• Smith+Nephew: Large public medical device company with significant advanced wound management and regenerative medicine portfolio (including acquired Osiris assets). Comparable as a scaled commercial channel and competitor in regenerative wound and tissue markets.
• Integra LifeSciences: Public medical device company (IART) with a regenerative tissue technologies portfolio (e.g., Integra dermal regeneration templates, amniotic membrane products). Larger incumbent with overlapping hospital channel and wound/regenerative medicine focus.

Direct peers

• Organogenesis: Public regenerative medicine company (ORGO) selling living cell-based wound care products (e.g., Apligraf, Dermagraft) derived from human cells. Comparable in selling regulated cell/tissue products to hospitals and clinical specialists via field sales.
• Community Tissue Services: Non-profit tissue bank providing allograft tissue for transplantation and regenerative medicine. Comparable as a peer AATB-accredited tissue bank with hospital/biotech distribution model.
• AlloSource: Non-profit tissue bank that manufactures allografts from donated human tissue for orthopedic, spine, sports medicine and wound care. Directly comparable as an AATB-accredited tissue processor supplying hospitals and OEMs.
• MiMedx Group: Public regenerative medicine company that processes and markets human placental tissue allografts (e.g., EpiFix, AmnioFix) for wound care and surgical applications. Closest direct competitor in the HCT/P birth-tissue space with overlapping homologous-use product strategy.
• Osiris Therapeutics (Smith+Nephew): Originally pioneered mesenchymal stem cell products (Grafix, OvationOS) from placental tissue; now part of Smith+Nephew. Highly comparable in MSC-based regenerative medicine product strategy and 361 HCT/P positioning.
• Vericel Corporation: Public cell therapy company (VCEL) commercializing autologous and allogeneic cell therapies (MACI, Epicel). Comparable as a specialized cell-based therapeutics company selling into hospitals and surgical specialists.

Emerging players

• Celularity Inc. Clinical-stage cell therapy company developing allogeneic placenta-derived cell therapies and biomaterial products. Comparable as a peer using birth tissue (placenta/umbilical cord) as raw material for regenerative medicine applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vitti-labs

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitti Labs